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Objective:
 
 To assess the cost-effectiveness of pharmaco-
therapy for male partners in screening women for as-
 
ymptomatic infection with 
 
Chlamydia trachomatis
 
 (CT).
 
Methods and Data:
 
 A pharmacoeconomic decision anal-
ysis model was constructed for the health outcomes of a
CT screening program, such as averted cases of pelvic
inflammatory disease and infertility (major outcomes).
Reinfection in the absence of partner pharmacotherapy
was included in the model. Cost-effectiveness from a
societal perspective was estimated for prevalence data
from a selective opportunistic screening program in Am-
sterdam. For diagnosis of asymptomatic CT infection a
Ligase Chain Reaction (LCR) test on urine was used;
for pharmacotherapy of women and partners azithro-
mycin was used. By linking health outcomes with health
care costs and productivity losses, averted costs were es-
timated. Cost-effectiveness was expressed as net costs
per major outcome averted.
 
Results:
 
 Partner pharmacotherapy reduces net costs per
major outcome averted of the screening program by ap-
proximately 50%. Sensitivity analysis indicates signifi-
cant improvements in cost-effectiveness of the screening
program, even when relevant assumptions are varied.
Within the broader framework of the screening program,
partner pharmacotherapy is a cost-saving activity.
 
Conclusions:
 
 Inclusion of partner pharmacotherapy pro-
vides significant improvements in overall cost-effectiveness
of the CT screening program among women aged 15 to 29.
Partner pharmacotherapy lowers net costs per major out-
come averted to the realm where implementation of the
screening program should be considered. Considering the
 
cost-saving potential, male partner pharmacotherapy should
be pursued within the broader framework of a CT screening
program for women. Reinfection should be included in any
future pharmacoeconomic model of CT screening. Further
work on this type of model should also be directed to
linking cost-effectiveness to epidemiological models for the
long-term spread of infectious diseases in populations.
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Introduction
 
This paper addresses cost-effectiveness of pharma-
cotherapy for partners of women found with as-
ymptomatic 
 
Chlamydia trachomatis
 
 (CT) infec-
tion. This topic is addressed as a logical extension
of a screening program for asymptomatic CT in
women. In general, there are some obvious reasons
to screen women for CT infection. Of CT infections
in women, 70% remain asymptomatic. Untreated
asymptomatic CT infection in women may cause
serious complications, such as pelvic inflammatory
disease (PID), chronic pelvic pain (CPP), and ec-
topic pregnancy and infertility, requiring complex
health care. Significant health gains and monetary
benefits can be achieved by screening and treating
women who are found to be CT positive [1,2].
Screening programs have become feasible with the
recent availability of highly convenient tests such
as the ligase chain reaction (LCR) urine test, and
highly effective treatment such as single-dose azi-
thromycin [3,4]. The benefits of a CT screening
program directed at women may, however, readily
disappear if CT-infected male sex partners do not
receive appropriate pharmacotherapy and thus re-
main able to reinfect the screened and effectively
treated woman.
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In contrast with other cost-effectiveness studies
of CT screening such as that carried out by Genç et
al. [5], we have included reinfection in the absence
of partner pharmacotherapy in our pharmacoeco-
nomic model. To our knowledge no other study has
yet been published in the international literature
that takes account of reinfection in CT screening
programs. Recent study findings show that male sex
partners of CT-infected women have a high chance
of being asymptomatically infected [6]. Therefore,
major benefits in averting reinfection can be ex-
pected from partner pharmacotherapy. The design
of our pharmacoeconomic model framework en-
ables us to quantify these benefits. Our model is de-
signed as a decision tree and corresponding decision
tree analysis reflects a reasonable first step toward a
more rigorous assessment of intervention, such as a
randomized trial of partner pharmacotherapy.
 
Methods
 
This pharmacoeconomic model was applied to
data from a pilot study of selective opportunistic
CT screening in 22 general practices throughout
the city of Amsterdam (the Netherlands) from May
1996 to May 1997 (the Amsterdam pilot study).
Heterosexually active young women (selective) vis-
iting the general practices for any reason (opportu-
nistic) were offered Abbott’s LCR-test on urine for
CT infection. Women who tested positive were of-
fered standard treatment with single-dose azithro-
mycin. Prevalence of CT infection over 6% was
found for women between the ages of 15 and 29 [7].
Currently, a screening program for women in this age
group is being considered for Amsterdam.
 
The Pharmacoeconomic Model
 
Our pharmacoeconomic model is a predictive de-
cision model that applies the societal perspective
combining:
• long-term progression of disease for untreated
asymptomatic CT infection in women;
• diagnosis and treatment of asymptomatic CT in-
fection for women participating in the screening;
• partner pharmacotherapy; and
• cost estimates for complications of untreated
asymptomatic CT.
Figure 1 Decision tree for screening of Chlamydia trachomatis including partner pharmacotherapy (woman is cured if therapy is
accepted and effective).
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The final output of the model is cost-effective-
ness, expressed as the ratio of monetary costs and
benefits to the number of averted complications.
For model design and analysis we used Microsoft
Excel 97 (Microsoft Inc., Redmond, WA) and DATA
3.5 for Health Care (TreeAge Software, Williams-
town, MA). Figure 1 reflects the complex decision
tree used. The details of the tree and data required are
explained below.
 
Progression of Disease
 
Table 1 lists the progression of disease for untreated
asymptomatic CT infection. For women, the compli-
cations of PID, CPP, ectopic pregnancy, and infertil-
ity are considered next to the possibility of vertical
mother-to-child transmission during pregnancy and
associated neonatal pneumonia and conjunctivitis.
Conditional probabilities for progression of disease
were derived from the international literature. Several
reviews and published expert opinions are already
available [8–13]. Furthermore, prior cost-effective-
ness analyses have listed progression of disease prob-
abilities [5,14–16]. Finally, results from a recent ran-
domized trial [17] and three cohort studies are
available [18–20]. Table 1 includes the exact value
and the reference applied in the model.
Adjusted probabilities were used to estimate the
adverse sequelae of CT infection linked to preg-
nancy. Adjustments were made for the age-specific
desire to become pregnant and specific Dutch fam-
ily planning conditions. Only women considering
future pregnancy were entered in calculations of
age-specific probabilities of becoming infertile due
to CT infection or of having an ectopic pregnancy
due to CT infection (estimates based on data for
1997 from the Central Bureau of Statistics, Voor-
burg). Additionally, only women giving birth while
infected with CT were considered in estimates of age-
specific probabilities for having a child with neo-
natal conjunctivitis and pneumonia caused by ver-
tical transmission of CT. Based on a Swedish fol-
low-up study, an infectious period of 52 weeks
was inserted in our model [21].
 
Screening
 
A conservative estimate of 80% for the sensitivity
of the LCR-test was applied [22,23]. Following a
positive test, pharmacotherapy with azithromycin
was suggested [24,25]. False positives were neglected
in the analysis, because specificity of the LCR-test of
100% has been reported [22]. Noncompliance, or
refusal to accept pharmacotherapy, was assumed to
be 10% (the percentage refusing pharmacotherapy
in the Amsterdam pilot study). Effectiveness of
azithromycin in eliminating complications was as-
sumed to be 95% [24].
The per-partner transmission rate, female to male
and male to female, has been reported as 68% [6].
For computing the probability of infecting male part-
ners, age-specific percentages for having a steady or
casual partnership during one year were used. These
percentages were multiplied by the average number
of male partners per year in steady partnerships and
in casual partnerships, which were 1 and 2.2, respec-
tively [26]. It was further assumed that all partners in
steady partnerships are current partners. Further-
more, one-third of the partners in casual partner-
ships were assumed to be ex-partners, one-third
current partners, and one-third partners in the near
future.
A male partner in the near future who might be
infected can be protected from infection by effec-
tive pharmacotherapy of the female, who is currently
asymptomatically infected. Men who are going to be
infected can develop both symptomatic urethritis
and epididymitis.
 
Partner Pharmacotherapy
 
Ex-partners and current partners of asymptomatic
woman are either asymptomatically infected or non-
infected. As mentioned, 68% of male partners are CT
infected. Of CT-infected men, half (34%) present
with symptomatic urethritis [8]. Symptomatically in-
fected male partners have visited the general practi-
tioner and have subsequently been treated. Further-
more, the asymptomatic CT-infected women might
have been contacted and received pharmacotherapy
and might therefore no longer be infected with CT.
Based on data for partner referral, approximately
60% of female partners of symptomatically infected
men are estimated to be cured [27]. Therefore, only
 
Table 1
 
Conditional probabilities (%) for complications of 
infection with 
 
Chlamydia trachomatis
 
 (CT)
 
Complication Probability (%) Condition
Pelvic Inflammatory 
Disease (PID)
25 [10] Asymptomatic CT infected 
woman
Symptomatic PID 40 [13] PID
Chronic pelvic pain 
(CPP)
18 [18] PID
Ectopic pregnancy 8 [20] PID
Infertility 11 [20] PID
Neonatal conjunctivitis 30 [10] CT-infected mother at 
birth
Neonatal pneumonia 15 [19] CT-infected mother at 
birth
Symptomatic urethritis 50 [11] CT-infected man
Epididymitis 2 [14] Asymptomatic CT-infected
man
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a minority of previously asymptomatically CT-
infected women with symptomatically infected
male partners remain asymptomatically infected.
Asymptomatic infection only remains if the woman
cannot be contacted, she refuses pharmacother-
apy, or pharmacotherapy is ineffective. These women
reflect approximately 15% of all women initially as-
ymptomatically CT infected. Together with 34% as-
ymptomatic CT-infected women with asymptomati-
cally infected male partners (see above) and 32%
with noninfected male partners (100%–68%), in to-
tal approximately 81% (15% 
 

 
 34% 
 

 
 32%) of
the women initially infected remain infected after the
process of partner pharmacotherapy. In consequence,
currently asymptomatic CT-infected women found in
the screening program have current and ex-partners
of which 42% are asymptomatically infected (34%
divided by 81%).
Prevention of complications of nonsymptom-
atic CT infection in men (primarily epididymitis)
was considered to be yet another benefit of tracing
ex- and current partners. Based on partner referral
data, we estimated that 86% of current male part-
ners were offered pharmacotherapy [27]. For male
ex-partners this percentage was 33% [27].
 
Cost Estimates
 
Table 2 shows the direct and indirect costs of the
considered conditions. Details on cost measure-
ment can be found in the Appendix. All costs were
calculated from a societal perspective and esti-
mated for the Dutch situation. Costs of complica-
tions in newborns were assigned to the year of CT
infection. Costs associated with PID were also as-
signed to this first year. It was assumed that CPP
occurs 5 years after PID [11]. Future costs were
discounted at a rate of 3% per year [28]. The in-
terval between CT infection and ectopic pregnancy
or infertility is inversely related to the age of the
woman at infection. Specifically, ectopic pregnancy
and diagnosis of infertility are assumed to occur 10
years after CT infection for women aged 15 to 19,
5 years after infection for women aged 20 to 24,
and 2 years after infection for women aged 25 to
34. For these age categories, costs of ectopic preg-
nancy and infertility management were appropri-
ately discounted.
 
Pharmacoeconomic Analysis
 
The Amsterdam Pilot Study.
 
The pharmacoeco-
nomic model was applied to prevalence of asymp-
tomatic CT infection from the Amsterdam pilot
study. Visitors of these GPs were eligible for en-
trance into the study if they considered themselves
heterosexually active and had no STD-related com-
plaints. Eligible visitors were asked to participate in
a CT screening program. Urine was send to a cen-
tral laboratory and tested by LCR for CT. Partici-
pation of eligible visitors was high (94%) and ulti-
mately 2403 women participated [7].
Test prevalences of sexually active women were
13.4, 7.3 and 5.5 for the age groups 15 to 19, 20
to 24 and 25 to 29, respectively. Taking into ac-
count the assumed sensitivity of the LCR-test, the
corresponding estimated prevalences were 16.8,
9.1, and 6.8, respectively.
 
Screening Strategies.
 
We considered a screening
strategy directed at women aged 15 to 29. Pharma-
cotherapy for current partners is covered by provid-
ing the woman with extra prescriptions for single-
dose azithromycin. For ex-partners, a prescription
for azithromycin is mailed. Because partners are pre-
scribed medication based on a high probability of
infection without the results of diagnostic serology,
this approach was labelled epidemiological phar-
macotherapy. As an alternative, test-based pharma-
cotherapy for partners was considered in the sensi-
tivity analysis: a GP visit for the partner, an LCR-test
for the partner, and if the test indicates CT infec-
tion, a prescription for pharmacotherapy. Accep-
tance of pharmacotherapy and of the test (only in
 
Table 2
 
Estimates of direct and indirect medical costs 
(€ 1996). Indirect costs are shown for persons aged 15 to 24 
(for persons aged 25 to 29 indirect costs are in parentheses)
 
Direct costs Indirect costs
PID
Inpatient care 3680 260 (600)
Outpatient care 60 120 (280)
CPP*
Inpatient care 3110 430 (650)
Outpatient care 550 200 (310)
Ectopic pregnancy* 2740 800 (800)
Infertility*
Inpatient evaluation 2180 200 (200)
Outpatient evaluation 760 270 (270)
In vitro fertilization* 1340 180 (180)
Neonatal conjunctivitis 40 Not applicable
Neonatal pneumonia
Inpatient care 15,200 Not applicable
Outpatient care 90 Not applicable
Symptomatic urethritis 40 8 (26)
Epididymitis
Inpatient care 2060 250 (790)
Outpatient care 80 130 (400)
 
*undiscounted figures.
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the test-based approach) among male partners
was assumed to equal that of the women.
 
Cost-Effectiveness.
 
The cost-effectiveness of a screen-
ing strategy was calculated as a weighted average of
age group–specific results. Weighting factors were de-
rived from the age distribution of Amsterdam women
in the age group 15 to 29 [29], age- and sex-specific
sexual activity [26], age-specific annual probabilities of
visiting a GP [30], and CT test acceptance [7].
The baseline results used the parameter estimates
introduced above. In univariate sensitivity analysis
we varied all of the baseline parameter values (Ta-
ble 3). The cost-effectiveness ratio is presented as
net costs per major outcome averted. PIDs, cases of
CPP, ectopic pregnancies, infertility, and neonatal
pneumonias were counted as major outcomes. As
suggested by some authors, health benefits such as
prevented cases of infertility were not discounted
(discount rate of 0%) [31]. Net costs reflect costs of
investing in the screening (tests, GP visits, pharma-
cotherapy) minus the averted costs of PID, CPP, ec-
topic pregnancy, infertility, neonatal pneumonia, neo-
natal conjunctivitis, epididymitis in male partners,
and urethritis in future male partners.
 
Reporting of Results.
 
Results are reported for cur-
rent test costs of 
 
€
 
16, including approximately 
 
€
 
2
for transport from the GP to the laboratory and
excluding value added tax (
 
€
 
1 
 

 
 US$0.85 on Oc-
tober 19, 2000). For the societal perspective cho-
sen, value added tax should be excluded from eco-
nomic evaluations, because this tax merely represents
transfers and does not affect the total welfare of soci-
ety. Because one might expect reductions in the cost
of the test for a large-scale screening, we included
test costs of 
 
€
 
10 in the sensitivity analysis. Further-
more, the GP was assumed to charge about 
 
€
 
10 per
tested woman in the screening program (this was
the amount that GPs in the Amsterdam pilot study
received for time investment and expenses). Costs of
pharmacotherapy amount to approximately 
 
€
 
14,
including the pharmacist dispensing fee, and finally,
 
€
 
0.50 was included for the costs of mailing a pre-
scription.
Results are reported for three options of the
pharmacoeconomic model. Option A refers to the
situation where reinfection is not considered (prob-
ability is set to zero) and no partner pharmacother-
apy occurs. As argued previously, option A reflects
costs-effectiveness as estimated by the current in-
ternational standard for calculating cost-effective-
ness for CT screening. Option B refers to the situa-
tion where the probability of reinfection is 68%,
but partner pharmacotherapy is absent. Worsen-
ing of cost-effectiveness in option B compared to
A reflects the adverse effects of reinfection. Option
C refers to the situation where the probability of
reinfection is 68% but reinfection is offset by part-
ner pharmacotherapy. Improvement of cost-effec-
tiveness in option C compared to B reflects the
beneficial effects of partner pharmacotherapy.
 
Results
 
Baseline Cost-Effectiveness
 
Table 4 lists cost-effectiveness estimates and con-
stituting elements for the three options of the model.
Cost-effectiveness as estimated according to the in-
ternational standard amounts to 
 
€
 
132 for screening
 
Table 3
 
Assumptions in baseline and sensitivity analysis
 
Baseline 
analysis
Sensitivity
analysis
Discount rate for costs (%) 3 0–7
Indirect costs Included Excluded
Probability for PID (%) 25 20
Test costs (
 
€
 
) 16 10
Sensitivity of LCR-tests (%) 80 90
Age-group for screening (years) 15–29 15–24
Discount rate for major outcomes 
averted (%)
0 3
Prevalence Pilot 
study
50% of 
pilot 
study
 
Table 4
 
Estimated investment costs, savings from averted complications, net costs, major outcomes averted, and net 
costs per major outcome averted of a screening program for 
 
Chlamydia trachomatis
 
 in Amsterdam women for three 
model options (
 
€
 
)
 
Option A 
No reinfection and
no partner pharmacotherapy
Option B 
Reinfection without 
partner pharmacotherapy
Option C 
Reinfection and
partner pharmacotherapy
Investment 1,185,700 1,185,700 1,227,100
Savings 1,033,700 638,000 880,200
Net costs 152,000 547,700 346,900
Outcomes averted 1,153 701 941
Cost-effectiveness ratio 132 781 368
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women aged 15 to 29 (option A). The investment in
screening and pharmacotherapy for women is esti-
mated at 
 
€
 
1.2 million for the whole city of Am-
sterdam. This investment is partly offset by a reduc-
tion by 
 
€
 
1.0 million in direct and indirect health
care costs for major outcomes. In total, an estimated
1153 major outcomes are averted.
Introducing reinfection in the model raises the
cost-effectiveness ratio to 
 
€
 
781. Investment stays
equal to option A, but savings are reduced by al-
most 50%. Net costs in option B are estimated to
surpass 
 
€
 
0.5 million for the city of Amsterdam as
a whole. Introducing partner pharmacotherapy into
the model reduces the cost-effectiveness ratio by
more than 50% from 
 
€
 
781 (option B) to 
 
€
 
368 (op-
tion C). Investment is slightly higher in option
C because some male partners receive pharmaco-
therapy. Net costs are estimated to be reduced by
 
€
 
200,000, indicating that partner pharmacother-
apy reduces costs within the broader screening frame-
work. Furthermore, partner pharmacotherapy averts
413 major outcomes (
 

 
 781–368).
In the model including reinfection and pharmaco-
therapy (option C), 941 major outcomes are averted
by the screening program. Figure 2 specifies the dis-
tribution of these 941 cases over PID, CPP, ectopic
pregnancy, infertility, and neonatal pneumonia.
Almost three-quarters of major outcomes averted
are cases of PID.
 
Sensitivity Analysis
 
Figure 3 shows the percentage reduction in the cost-
effectiveness ratio through introducing partner phar-
macotherapy in sensitivity analysis, i.e., options B
and C are compared in a set of situations. Reductions
remain below 50% if the discount rate is raised to
7%, if only direct costs are considered (indirect costs
are excluded), if the progression rate to PID is low-
 
ered from 25% to 20%, if the prevalence of CT is
lowered by 50%, and if test-based treatment of part-
ners is applied. In the first four situations monetary
benefits of major outcomes averted are lowered; in
the last situation investment costs in partner phar-
macotherapy are raised. If a lower prevalence is
considered, both costs of pharmacotherapy and
monetary benefits of major outcomes averted are
lowered. Lowering prevalence may reflect situa-
tions outside the Amsterdam pilot study.
In the remaining situations, the reduction in the
cost-effectiveness ratio resulting from partner phar-
macotherapy surpasses 50% as in the baseline. The
reduction of 95% that would result if test costs
could be lowered to 
 
€
 
10 reflects cost-effectiveness
ratios of 
 
€
 
310 without partner pharmacotherapy
and 
 
€
 
15 with partner pharmacotherapy. This im-
plies that almost a break-even situation is achieved,
because investment costs in the screening and part-
ner pharmacotherapy are almost leveled by benefits
of averted direct and indirect costs of major out-
comes. A reduction of over 60% in the cost-effec-
tiveness ratio due to partner pharmacotherapy re-
flects the situation of screening women aged 15 to
24 only. Finally, it is shown that discounting health
gains has minimal impact on our analysis, because
the majority of major outcomes averted take place
immediately (PID and neonatal pneumonia; see
Fig. 2).
The gross picture from the sensitivity analysis is
that partner pharmacotherapy provides good po-
Figure 2 Percentage distribution of major outcomes averted.
Figure 3 Sensitivity analysis of reduction in net costs per
major outcome averted by partner pharmacotherapy (in com-
parison with no partner pharmacotherapy and maximum as-
sociated reinfection).
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tential for achieving major reductions in the cost-
effectiveness ratio for a screening program for CT
in women. The range derived in the sensitivity anal-
ysis indicates percentage reductions from 30% up
to 95%.
One further point to be considered is the ac-
ceptability of pharmacotherapy among male part-
ners. This was assumed to be 90% (i.e., 90% of
the traced partners would actually take the azithro-
mycin). This could be considered too optimistic an
assumption. However, even when acceptability is
lower, partner pharmacotherapy is cost saving as
long as acceptability remains above 8%. Obvi-
ously, this threshold is low enough to ensure cost
saving of partner pharmacotherapy in the broader
screening program framework.
 
Discussion
 
Application of our pharmacoeconomic model shows
good potential for improving cost-effectiveness of
screening women for CT infection by including phar-
macotherapy for male partners. Net costs per ma-
jor outcome averted are reduced by approximately
50% if pharmacotherapy is introduced in the screen-
ing program framework. This is primarily due to pre-
vention of reinfection in women who have been
cured through the screening. Furthermore, small ben-
efits exist in preventing short- and long-term symp-
toms of CT infection in men. Within the screening
framework, male partner pharmacotherapy is a cost
saving activity.
Our results indicate that benefits of averted di-
rect and indirect costs do not surpass investment
costs (screening and partner pharmacotherapy) for
the whole screening program in the short term.
Society has to incur net costs for the prevention of
CT complications. We have shown that the pre-
vention of one major outcome by screening costs
approximately 
 
€
 
370. One could argue that this is
a reasonable cost for preventing infertility, consid-
ering the loss in quality of life for many years that
can be presumed. Furthermore, there exist several
other prevention programs in infectious diseases
for which society must pay net costs to avert
complications, such as influenza vaccination and
screening for HIV [32,33].
 
Conclusions, Methodological Advances, and 
Further Work
 
Our conclusion is that male partner pharmaco-
therapy significantly improves the cost-effective-
ness of a screening program for CT in women aged
15 to 29 in Amsterdam general practice. Male
partner pharmacotherapy is a cost-saving activity
in the screening program as a whole. From a phar-
macoeconomic point of view, CT screening that
includes partner pharmacotherapy appears worth-
while. Cost-saving activities in health care should
always be pursued from a pharmacoeconomic point
of view. Obviously, pharmacoeconomics is only one
of several factors to consider before implementing a
health care program, others being ethical, budget-
ary and sociocultural factors.
We have shown that reinfection is a major de-
terminant of the cost-effectiveness for CT screen-
ing. As models neglecting reinfection have been the
standard until now, many of the previous studies
on CT screening may have incorrectly estimated cost-
effectiveness. In consequence, this paper represents
a major step in improving the methodology of cost-
effectiveness analysis in CT screening in particular,
and as reinfection is a widespread problem in medi-
cine, in the field of infectious disease in general.
Further development of our cost-effectiveness
model could be directed at the time horizon. Our
framework is, in accordance with the international
norm for this type of model [5], limited to a time
horizon up to 1 year after screening. However, as
the screening program will affect the prevalence of
CT infection in the population and therefore the
potential to further spread the infection, the point
of departure is different for following years. To
fully comprehend these interactions between screen-
ing and epidemiology, the cost-effectiveness frame-
work should comprise a long-term period of several
years of screening and should be linked to an epide-
miological model for the spread of CT infection in
women and men [34,35]. This does, however, sig-
nificantly complicate the analysis, increase data
needs and hamper local applicability of the model.
Our current approach lacks these disadvantages,
whereas it does present an important methodolog-
ical step forward by including effects of partner
pharmacotherapy.
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Appendix: Cost Measurement Details
To estimate direct medical costs, information on
health care needs was gathered and linked to unit
cost prices. Dutch data on health care were pre-
ferred, but not always available. In the absence of
Dutch data, assumptions were drawn from other
country settings, neglecting practice pattern differ-
ences. It was assumed that symptomatic PID is
treated on an outpatient basis in 75% of cases
[1]and involves two GP visits, medication, an LCR-
test for CT, and a test for Neisseria gonorrhoeae.
Inpatient treatment of the remaining 25% involved
9.6 inpatient days [2], diagnostic laparoscopy, and
medication. The medication for PID as well as those
for symptomatic urethritis, epididymitis, neonatal
pneumonia and conjunctivitis were obtained from
the 1998 Centers for Disease Control guidelines
for the treatment of CT complications [3]. Health
care needs for ectopic pregnancy, infertility and in
vitro fertilization were derived from a previous Dutch
study [4]. It was assumed that infertility was evalu-
ated in an outpatient setting in 53% of cases, in an
inpatient setting in 13% of cases and was not
evaluated in the remaining cases. In vitro fertiliza-
tion (average 2.11 times per couple) was assumed
to occur for 23% of evaluated infertility. It was
assumed that CPP was treated with analgesic drugs,
pelvic ultrasonography, and ambulatory laparos-
copy for 75% of patients [5]. Furthermore, outpa-
tient treatment was assumed to involve 10 ap-
pointments with a physician (three with a GP and
seven with a gynecologist). For inpatient care, two
appointments with a gynecologist and hospitaliza-
tion for the same duration as inpatient treatment
of PID preceded by one GP appointment was as-
sumed. 70% of CPP cases were assumed to be out-
patient treated and 30% inpatient [6]. Due to lack
of reliable information, no surgery was considered;
therefore, costs for CPP are a conservative estimate.
Neonatal conjunctivitis involves tests for CT
and Neisseria gonorrhoeae, and medication. Out-
patient care of neonatal pneumonia involves one
GP visit, two visits to a pediatrician, a test for CT,
and medication. One GP visit and 13 days of neo-
natal hospital inpatient care were assumed for 10%
of pneumonia cases [2,4]. Treatment of symptom-
atic urethritis in men was assumed to involve one
GP visit, tests for CT and Neisseria gonorrhoeae,
and a prescription for antibiotics. Finally, it was as-
sumed that epididymitis involves one GP visit, tests
for Neisseria gonorrhoeae and CT, and medication.
Inpatient treatment for 15% of the cases with epid-
idymitis involved 7.1 days of hospitalization [2,6].
Deflators for Gross Domestic Product were used
to recalculate all costs in 1996 prices. Estimated
costs of €1090 for intensive care were applied to
an inpatient hospital day for neonatal care [7] (ex-
change rate as of October 10, 2000: €1  US$0.85).
Hotel costs for a hospital inpatient day for an adult
were estimated at €290 [8]. Fees for examinations
and treatment were used to calculate costs for hospi-
tal activities (provided by the Academic Hospital
Groningen). Costs of in vitro fertilization were esti-
mated at €1340 per treatment [4]. Calculation of
in-hospital medication costs was done using market
prices for standard prescriptions [9]. The average
GP charge for publicly and privately insured per-
sons was almost €15 [10].
The indirect costs of CT infections were estimated
by valuing the loss of productivity. For valuing the
loss of productivity in terms of paid work, average
labor costs by age and sex were used to approximate
the net product. Based on an analysis of labor costs
in the Netherlands, the average Dutch gross in-
comes by age and sex were adjusted and inflated
to derive average Dutch labor costs for 1996 [11].
These were multiplied by the employed labor force
participation rate, specified by age and sex, yield-
ing the yearly net product per capita resulting
from paid work [11]. Using findings from the lit-
erature, 10 days of productivity were estimated to
be lost for each outpatient PID treatment or CPP
treatment, 21 days for each case of inpatient PID
or chronic pelvic pain, and 28 days for each case
of ectopic pregnancy [12]. A case of epididymitis
was estimated to cause a productivity loss of 10
(inpatient treatment) or 5 (outpatient treatment)
days. Assuming that an ambulatory visit costs half a
working day and a GP contact 1.5 hours, the loss of
productivity due to infertility management (5 days
plus 4.5 hours lost for outpatient management, 4.5
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days for inpatient management), in vitro fertilization
(4 days lost), and symptomatic urethritis in men (1.5
hours lost) were computed. Indirect costs because of
the loss of unpaid work (e.g., household work) were
not considered.
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